key: cord-0735699-wfegzsng authors: Trapani, D.; Marra, A.; Curigliano, G. title: The experience on COVID-19 and cancer from an oncology hub institution in Milan, Lombardy Region date: 2020-04-29 journal: Eur J Cancer DOI: 10.1016/j.ejca.2020.04.017 sha: b3ff4b6b63132e075fd41072b70bf0ead6abfabb doc_id: 735699 cord_uid: wfegzsng Abstract The rapid outbreak of the SARS-CoV-2 related disease (COVID-19) has spread rapidly to a pandemic proportion, increasing the demands on health systems for the containment and management of COVID-19. Cancer has been reported as a major risk factor for adverse outcomes of and death from COVID-19. We extracted data from the World Health Organization’s progress reports and from the Italian Council of Medicine. In addition, we retrieved clinical data on cancer patients with confirmed COVID-19 in our Institution. As of April 2nd, 2020, 110 574 COVID-19 cases and 13 157 deaths have been described in Italy, representing a global share of 5.1% and 28.9% for incidence and mortality, respectively. In Italy, we report the analysis of the Italian Medical Council on 909 patients who died from COVID-19, of whom 16.5% were cancer patients. The population was enriched with subjects with multiple co-morbid non-communicable diseases, with less than 1% of the population presenting no co-morbid conditions. At the patient level, we identified nine patients referred to our department in the last two months who were receiving standard of care or experimental medications in the curative and palliative settings. The median age was 68 years (range: 42–79 years), and patients carried a median of one co-morbid condition (0–2); two out of nine patients presented with severe COVID-19 presentation, and were receiving inpatient care. None of the patients receiving immunotherapy experienced severe adverse outcomes, and four patients were discharged with complete reversal of the clinical syndrome and SARS-CoV-2 clearance. Learning from the experience of countries with a high burden, efforts must be made to assure the access of cancer patients to treatments, prioritizing the cancer health interventions based on their intrinsic value, and limiting the exposure to an unacceptable risk of infection for both health providers and patients. Any significant work in the design and implementation of health system actions, including in clinical care, must be framed as an initiative under the Global Response Agenda and through a community approach, with the intention of pursuing common goals to tackle COVID-19 and cancer, as ‘One Community’ working for ‘One Health’s. The outbreak of the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) has rapidly spread worldwide to a pandemic proportion. As of April 2nd, 2020, the World Health Organization reported 896 450 confirmed cases, with 45 526 deaths from SARS-CoV-2-related disease . Of them, 110 574 cases and 13 157 deaths have been described in Italy, representing a global share of 5.1% and 28.9% for incidence and mortality, respectively [1] . The rapid spread of the pandemic has challenged the capacity of the Italian health system, demanding the strongest resilience in the design and implementation of an emergency plan for both preparedness and response. The rapid adoption of non-pharmacological public health interventions, such as social distancing and lockdown measures, has driven the initial response to an unprecedent extent for the national health system. The national capacity of Italy's health system has traditionally been regarded as an excellent model for a public health service, ensuring effective coverage for all, with 3.12 hospital beds per 1000 people and 3.99 physicians per 1000 inhabitants [2]; the system has been able to deliver efficient and effective healthcare, favoring the country in terms of productivity [3] . However, no health system can be truly prepared or sufficiently flexible for an impressive rise in the demand for intensive care capacity, especially if funded on vertical disease programs. An academic health model anticipated complete saturation of the number of available beds in intensive care units by March 14th, 2020, prompting an inter-sectorial approach that could clearly estimate and communicate the risk for severe COVID-19 cases requiring intensive care [4] . Such an approach broadens the chances for all to access the appropriate treatments, while the daily rate of new COVID-19 cases requiring hospitalization was slowing down. Since the beginning of the COVID-19 epidemic, older subjects and patients with noncommunicable diseases (NCDs), including cancer, have been shown to be at increased risk of severe complications and poor outcomes from COVID-19 [5] . Accordingly, protecting such vulnerable patient populations more than ever became a priority. In this regard, cancer care 2 was immediately established as a heath priority by the National Medical Council and the Ministry of Health. At the center of the outbreak: reorganizing cancer care to respond to COVID-19 in the Lombardy Region The Lombardy Region was the epicenter of the outbreak of COVID-19 in Italy [6] . In order to face the emergency, the Lombardy Region created differentiated pathways for COVID-19-and non-COVID-19-related health services. While segregation of the patients-and to some extent of the workforce-has been proposed by multiple decision-makers and framed in policies for the response to the pandemic, cancer patients can still experience a spectrum of SARS-CoV-2related health conditions; these include asymptomatic or pauci-symptomatic infections with subclinical courses which can be managed while the patient resides at home and is referred to the telemedicine systems and the primary healthcare network. Tackling a public health emergency while strategizing the care system has defined the priorities and modalities of the emergency response in the Lombardy Region for all patients. The rapid outbreak of COVID-19 in the Lombardy Region in Italy has prompted an urgent response to meet the needs of patient care while maintaining essential health care for all. As the pandemic rapidly escalated, the Italian Government enforced a state of emergency on a national scale [7] . Furthermore, the regional organs of governance and the emergency regulations emphasized the need to ensure essential care for cancer patients, a potentially frailer fringe of the population, exposed to both a higher risk of COVID-19 and fatal consequences [8, 9] . The bedrock for priority setting in oncology care is structured in value-based health system planning. Where no significant impairment of the prognosis is anticipated by temporary cessation of the service or changed eligibility conditions, a delay in the treatment can be tolerated [10] . On March 8 th , a Regional Council resolution was implemented, arranging a reorganization of the hospital networks based on a hub/spoke design [11] . The hubs for cancer care are designated on the base of performance criteria (e.g. volumes of specialized cancer surgery), each connected to one or more spokes for selected services (e.g. administration of standard 2 chemotherapies). The resolution aimed to assure the continuity of care for essential cancer treatments whilst urging a scale-up of the capacity for the serious healthcare demands of COVID-19; the system is operationalized to also tackle the health needs for all non-COVID-19 patients. The Lombardy Region defined new trajectories for the public-private relations, re-modulated by temporarily abrogating the private for-profit activities, thus extending the service availability to cancer patients. The Region provides comprehensive cancer centers, in the public and private sectors, along with several specialized departments, as eligible for building the hub-andspoke network. The specialized hubs for oncology have been connected with spokes to design a parallel health network for the specific referral of cancer patients, distinct from the 'COVID Italy" based on data available on March 30th, 2020 [12] . The present report describes the characteristics of 10 026 COVID-19 patients who died in Italy since the beginning of the disease registration, at the end of February 2020. The National registration system-coordinated by the COVID-19 Surveillance Group under the leadership of the Medical Council and the auspices of the Ministry of Health-includes all the cases of COVID-19 diagnosed locally and confirmed centrally in national reference laboratories across the 19 regions and two autonomous provinces. Patients dying from COVID-19 were generally older, with a median age of 78 years (range 26-100 years), of whom around 70% were men (n = 6938; 69%). When pooled by age groups, 111 patients died before the age of 50 years, encompassing 1.1% of the population, while a half of all these patients were older than 80 years (n = 4924; 49.1%). Disaggregation by gender indicated that women died at an older age than men (median 82 versus 78 years, respectively). Data on 909 patients who died in hospital were reported in depth, with a review of the source documents and the medical records [12] . Patients experiencing a fatal outcome from COVID-19 commonly carried a median of three NCDs as co-morbidities. More than 50% (n = 470) presented three or more co-morbid conditions, including ischemic heart disease, atrial fibrillation, heart failure, stroke, hypertension, diabetes mellitus, dementia, chronic respiratory disease, cancer, kidney or liver diseases. Few patients (only 2.1%, n = 19) had no co-morbid conditions. Fifteen patients out of 21 who died aged under the age of 40 years had pre-existing serious NCD comorbidities, and none had a history of cancer. The diagnosis of cancer was recorded only for patients treated for a malignancy in the past 5 years, and included both cured patients and those receiving active treatment before the COVID-19-related hospitalization. In the sample analyzed, 150 COVID-19 patients (16.5%) were cancer patients. According to the report, the majority of cancer patients were hospitalized for respiratory symptoms and/or pulmonary findings at imaging; overall, only 46 patients (in the entire series) were hospitalized for other medical reasons. Interestingly, of all cancer patients, 4.7% (7/150) were initially hospitalized for cancer treatment and not for the SARS-CoV-2 infection. Almost all the patients (96.5%) experienced a respiratory distress syndrome with acute onset (ARDS), 25.7% had acute kidney failure, and 11.2% were diagnosed with a secondary infection superimposed on the SARS-CoV-2 infection. Of interest, cardiac injury was reported for 11.6% of patients who died, both as a consequence of the blood gas and hemodynamic changes in ARDS patients and possibly via vascular or direct myocardial effects of the virus [13] . The Medical Council is committed to updating the progress reports on a periodic basis, especially when identifying relevant data on the clinical management of patients and on policy formulations. So far, no data on the treatments received by the patients and the status of the malignancy when COVID-19 was diagnosed has been released. Only a single report of an Italian cancer patient has been published so far [14] ; this described the case of a 65-year-old patient with metastatic non-small-cell lung cancer who had been receiving the anti-PD1 nivolumab with a sustained response of more than 6 years. After COVID-19 diagnosis and hospitalization, the patient presented a rapid worsening of pulmonary function that caused death on the 5th day of hospitalization. The authors suggested that the patient was still progression-free at the time of death, reporting a COVID-19-related death in a long-term controlled metastatic lung cancer; this recalls the need for a deeper discussion within the multidisciplinary teams when intensive care is a life-saving option in selected cases of patients with advanced and long-responding disease. Since the outbreak in late February, first the cancer institutions in Lombardy Region, and then those nationally, have reshaped the service delivery model and set priorities in cancer care. Treatment decisions have been initially provided on a case-by-case basis, aiming to meet the safety of the patients and balance against the risk of disease progression, with an impact on the outcome. To better understand the circumstances and the burden of COVID-19 and cancer, we collected the data from our institution. We extracted the data of laboratory-diagnosed COVID-19 patients who had been referred to our division from 1st February 2020, and retrospectively gathered clinicopathological data. As of 2nd April, 2020, the oncology team at the European Institute of Oncology in Lombardy Region have managed nine patients diagnosed with COVID-19, both as inpatients (n = 3) and as outpatients (n = 6), all in good general condition as per performance status (Table 1) . Of these, the majority of patients were male (n = 7). The median age was 68 years (range 42-79 years). The men were generally older than the women with a median age of 68 and 55 years, 2 respectively. All the patients had a smoking history, being either former smokers (n = 4) or current smokers (n = 5). No recurrent pattern of cancer type (per histology) or setting of care (neo/adjuvant or palliative) was identified; three patients were receiving active treatment in the curative setting and five were receiving treatment for metastatic disease, all received within 14 days at the time of COVID-19 diagnosis. Chemotherapy was the most common ongoing therapy (n = 4), followed by experimental immune checkpoint inhibitors (n = 2) and small molecules (n = 2). Possibly related to the inclusion in clinical trials, multiple NCD comorbidities were uncommon in the overall population, with a median of one comorbidity per patient (range: 0-2), represented by arterial hypertension (n = 4), diabetes mellitus type II (n = 2) and chronic kidney diseases (n = 1). Using the criteria to score SARS-CoV-2 infection proposed by the Italian Association of Anesthesiology, Analgesia, Resuscitation and Intensive Care (SIAARTI), we scored the COVID-19 severity in six stages-from stage I (non-complicated COVID-19, no pulmonary findings) to stage VI (septic shock)-and referred to stage 2 pneumonias as mild and stage 3 as severe. None of our patients accessed the intensive therapy unit; two had severe pneumonia and were hospitalized. All the other patients had a mild COVID-19 syndrome and were referred to home-based management, according to the local practice and clinical indications. For patients managed at home, a telemedicine system intended to connect doctors and nurses on a daily basis has been established, engaging with the primary health providers, and enhanced by the home delivery of territorial volunteers, community workers and nurses for specific tasks: registering vital parameters twice daily along with documentation of the patients' symptoms. Three patients, one with severe and two with mild pneumonia, were discharged and/or the clinical syndrome resolved, testing negative on SARS-CoV-2 laboratory assessment. While no specific pattern of increasing risk was recognized in this small series, it is interesting to report that none of our patients experiencing severe outcomes from COVID-19 or requiring hospitalization was receiving immunotherapy, a speculated risk factor for severe COVID-19. We report the first Italian series of cancer patients experiencing COVID-19 referred to our institution in the last two months. Making comparisons between the Italian situation and that in other countries may not be ideal, as the population demography and modifying effects of NCDs on the risk and prognosis of COVID-19 can affect the epidemiology of the disease, as can a diverse response and implementation of restrictive measures at community level. According to the data of the Chinese case series, with special reference to the national epicenter Wuhan, an older population and multiple co-morbid patients soon appeared to have the highest risk of adverse outcomes from COVID-19, especially if they had NCDs. In China, 25.3% of the population are older and potentially frail (Table 2 ). Almost 50% of the males in the population are tobacco-smokers. NCDs account for a significant proportion of the total mortality in the country, with cancer accounting for 23% of the patients succumbing to NCDs. The large patient series from Wuhan (n = 1099 patients) showed that the subjects with COVID-19 and selected NCDs tended to present a worse disease severity, co-morbidities including diabetes mellitus, hypertension, coronary artery disease, chronic kidney disease and cancer [5, 15] . In the correlation analysis of selected risk factors associated with ARDS or mortality in 201 patients [15] , older age and NCDs seemed to drive the prognosis for COVID-19. Hypertension, cardiovascular diseases and diabetes were more common in the patients experiencing an adverse outcome from ARDS, or dying of respiratory failure, with absolute differences ranging between 3.4% and 14%. The hazard ratios for ARDS and death were 1.82 and 1.7 for hypertension and 2.34 and 1.58 for diabetes, respectively. Although no cancer patient was included in the analysis, and few cancer patients have been reported across different Chinese studies, NCD comorbidities occur commonly in patients with cancer, both those receiving treatments and survivors, and some of them can be a direct consequence of the antineoplastic treatments [16] . with tobacco-related tumors. In this study, cancer history represented the strongest single prognostic factor for severe events in COVID-19 (odd ratio: 5.399), more than age and the presence of other NCDs. When analyzing the data only from the cohort of cancer patients, age was the only risk factor for severe events (OR 1.43). This finding is consistent with the previous reports on all the COVID-19 patients, where age was an independent prognostic factor for adverse outcome or mortality [15] . For patients receiving active antitumor treatments, poor prognosis seemed to be dictated by the interval between the COVID-19 diagnosis and the last treatment received (≤14 days), as recently reported [9] . Differences between the populations can be readily described, possibly explaining some divergences in the data. Italians are older, on average, with a larger proportion of the population, being older, deserving special care and risk protection. The number of smokers is lower among men but better balanced across the genders. Cancer is causative of death in more than 25% of all NCD-related mortalities, the second cause after cardiovascular diseases (Table 2 ). Overall, the ageing population and the burden of NCDs could partly affect the COVID-19 patients and determine a different case fatality rate, including for multi-comorbid cancer patients. On the other hand, our series must be regarded under the lens of the health context and referral pathways of our institution. The European Institute of Oncology currently serves the oncology network to assure cancer care as one coordinating hub. Patients are referred to the institution from other regions for disease-oriented second opinions and multidisciplinary expert discussions, to receive cancer treatments and to participate in clinical trials, especially early-2 phase studies. In that regard, all the patients in our series treated with study medications were enrolled in phase I and II trials. A possible shift to a lower comorbid cancer population, when compared with the Chinese and Italian national series, can be readily explained by the research mandate of the institutions, as a significant proportion of patients were receiving experimental compounds when experiencing COVID-19. The often restrictive eligibility criteria for the enrollment in clinical trials inevitably affect the population type, determining a shift to a lower-risk population for type and severity of comorbidities, and perhaps resulting in less severe outcomes for COVID-19. We report a mixed cohort of patients with diverse histology types and settings of care. While the previous studies seemed to be augmented with some cancer patients, like smoke-related malignancies, lung cancer diagnosis could itself represent a possible risk factor for severe outcomes from the infection, as observed in single case reports and case series. One of the two patients with severe COVID-19 hospitalized in our study is a patient with oncogene-addicted lung cancer and no comorbidities, receiving a targeted therapy. Of interest, the age range of our population falls halfway between the national median age for COVID-19 diagnosis and death. So far, we have observed no death from COVID-19 in our patients, and all the standard protocols for homebased management and regional criteria for hospitalization have been strictly followed. Cancer and COVID-19 still today represent an under-studied field, including the few cases in the Chinese series and the poor data so far derived therefrom. We report here the first Italian series. Given that cancer is an independent risk factor for adverse outcome and mortality from COVID-19, an in-depth analysis of the cancer series is highly attractive, as advocated by national institutions, including the Italian Association of Medical Oncology (AIOM) and reference experts with local initiatives and regional networks. The questions of the medical oncology for the correct approach in the management of COVID-19 are still multiple and unresolved, in the absence of data; questions include whether there is a need to stop certain types of treatments, and whether there is a risk of impairing outcome when continuing some medications with immune-regulating properties (both suppressing and stimulating). However, experience of colleagues facing COVID-19 successfully must be considered to understand the broader 2 landscape around cancer patients, persons living in societies and affected by the health environment they live in and how it is shaped by policy formulations and implementations. The experience from Singapore has recently been reported by Ngoi et al. [17] . The key to success of the oncology care envisioned by the authors is embedded in a strong population and resilient health-system response to the outbreak, across three principal directives: protect and empower the health workforce, prioritize the resources for cancer care for judicious allocation, and ensure coordination mechanisms for the health institutions with the regional, national and global policies and workflows. The implementation of a systematized response of the cancer providers, aligned to the national and regional priorities for the communities, in a population health perspective, has resulted in a reduction in the outpatient clinical workload (20% less) and inpatient admissions (30% less) of the National University Cancer Institute of Singapore. Over a period of 1 month, a model of segregation of the workforce has been established, to create parallel cohorts of providers for clinical care, education and research -with no reciprocal connections and a triage mechanism for the access of patients in the institutions. The authors reported only 34 patient admissions due to suspected SARS-CoV-2 during this period, and only one confirmed case that required mechanical ventilation in the intensive care unit. These data suggest that the bedrock to protect the vulnerable population is not single-institutional decisions, recommendations and guidelines, and the role of the single providers working in isolation can be irrelevant or even harmful when not synchronized under a common agenda for preparedness and response, with a community mandate and based on a coordination mechanism for the urgent reorganization of the healthcare delivery system, including separate referral pathways for patients with confirmed COVID-19. As all the oncologists in the world are pursuing the maintenance of the best care based on a priority-setting mechanism of health interventions, determined by their intrinsic values, the central driver to optimize clinical care should be enhanced via research implementation and less according to perspectives and opinions. This is a race where everybody must win: the application of science must be intended not just in terms of scale, but in the logic of a global security issue, intersecting the political will and global commitment to ensure health care for all [18] . It must be clear that the most critical element to champion in health and society in the response to COVID-19 is social responsibility: cancer patients are frail persons, and potentially more vulnerable; their protection must be ensured under a societal coordination mechanism for the prevention of the infection, the early recognition of the symptoms, isolation protocols, and the prompt initiation of treatments. The goal of a one-society approach to assure one health encircles cancer patients' special needs, as demanding protection and unique care, committing to formulate recommendations and perspectives under a multidisciplinary and intersectoral coordination system, shaped punctually within the agenda of the global response; any distraction must be tackled and rejected. The key for success in COVID-19 and cancer is to ensure a continuum of health care, never disconnecting the cancer cause from the population health needs, understanding and implementing the scopes and goals of the global responses, and enforcing community flexibility, and not merely advocating for a patient-centered approach. The resilience, capacities, skills and resources of the context must be recognized and these built on to deliver protection and solutions while supporting the community's own goal. The ultimate goal now is to end COVID-19 as one global community. World Health Organization Italy's health performance, 1990-2017: findings from the Global Burden of Disease Study COVID-19 and Italy: what next? Lancet Clinical Characteristics of Coronavirus Disease 2019 in China The response of Milan's Emergency Medical System to the COVID-19 outbreak in Italy concerning urgent measures regarding the containment and management of the epidemiological emergency COVID-19, and subsequent updates and changes Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan Italian Ministry of Health. Recommendations for the management of hematology and oncology patients during the COVID-19 public health emergency ) concerning new additional determinations concerning the epidemiological COVID-19 public health emergency 25f781d8756c/DGR+2906+8+marzo+2020.pdf?MOD=AJPERES&CACHEID=ROOTWORKSPACE-5e0deec4-caca-409c-825b-25f781d8756c-n2.vCsc. Accessed on: 13 Characteristics of COVID-19 patients dying in Italy First Case of COVID-19 Infection with Fulminant Myocarditis Complication: Case Report and Insights A rapid fatal evolution of Coronavirus Disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Comparison of Comorbid Conditions Between Cancer Survivors and Age-Matched Patients Without Cancer A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore COVID-19 needs a Manhattan Project The authors express sincerest gratitude to the patients and their families, the medical staff (doctors, nurses, scientists, health and administrative personnel) for their strenuous work in such a delicate moment for health care, ensuring the protection of the best cancer care for all. This work received no financial support. GC conceived and supervised the work. DT and AM collected the data and provided the data analysis. DT cross-referenced the data with external source references and datasets. All the authors contributed to writing and drafting the manuscript. All the authors read and approved the final proof of the manuscript. GC has received honoraria from Pfizer, Novartis, Lilly, Roche; fees for expert testimony and medical education from Pfizer; and has participated in advisory boards for Pfizer, Roche, Lilly, Ellipses Pharma, Novartis, Seattle Genetics, Celltrion. AM and DT have no potential conflicts of interest to disclose. • 1% of patients with COVID-19 in the series reported as cancer patients, 50% experienced a severe or fatal event;• in Italy, 16.5% of patients dying from COVID-19 are cancer patients.• In the first Italian series of cancer patients with COVID-19 receiving active treatment, 22% experienced severe presentation.• Research is emphasized to enhance knowledge on COVID-19 & cancer care, under a global response through community healthcare.• An intersectoral line must be pursued for this PH emergency, providing prevention & control measures to cancer patients.